• Profile
Close

In vivo availability of cannabinoid 1 receptor levels in patients with first-episode psychosis

JAMA Oct 11, 2019

Borgan F, Laurikainen H, Veronese M, et al. - In this cross-sectional case-control study of 58 males, researchers examined cannabinoid 1 receptor (CB1R, G-protein–coupled receptors expressed on presynaptic nerve terminals of excitatory and inhibitory neurons throughout the cortex, thalamus, hippocampus, and striatum) availability in first-episode psychosis without the confounds of illness chronicity or the use of illegal substances or antipsychotics. In antipsychotic-treated and untreated cohorts in relation to matched controls, the availability of CB1R was lower. Exploratory analyses intimated that in male patients, greater decreases in CB1R levels were related to greater symptom severity and poorer cognitive functioning. These findings imply that for the treatment of psychotic disorders, CB1R could be a possible target.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay